bluebird bio, Inc. (BLUE) has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (HTGC). The term loan facility provides for up to $175 million of term loans in aggregate, available in four tranches. Upon closing, the first tranche of $75 million was drawn. The company will be eligible to draw two additional tranches of $25 million each, subject to the achievement of commercial milestones.
bluebird bio said, based on launch trajectory and current business plans, and assuming three tranches totaling $125 million are executed, the transaction is expected to extend the company' cash runway through the first quarter of 2026.
Shares of bluebird bio are up 2% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.